A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder
about
Quality of life in children and adolescents with bipolar I depression treated with olanzapine/fluoxetine combinationRandomized controlled trials of serotonin-norepinephrine reuptake inhibitor in treating major depressive disorder in children and adolescents: a meta-analysis of efficacy and acceptabilityEfficacy and Safety of Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, and Placebo for Common Psychiatric Disorders Among Children and Adolescents: A Systematic Review and Meta-analysis.Placebo Response in Pediatric Anxiety Disorders: Results from the Child/Adolescent Anxiety Multimodal Study.Pharmacological treatment of children and adolescents with depression.Update on the Use of SSRIs and SNRIs with Children and Adolescents in Clinical Practice.Primary Pediatric Care Psychopharmacology: Focus on Medications for ADHD, Depression, and Anxiety.Placebo Response in Pediatric Anxiety Disorders: Implications for Clinical Trial Design and Interpretation.Pharmacokinetics of orally administered duloxetine in children and adolescents with major depressive disorder.A meta-analysis of effects of selective serotonin reuptake inhibitors on blood pressure in depression treatment: outcomes from placebo and serotonin and noradrenaline reuptake inhibitor controlled trials.Generalizability of Clinical Trial Results for Adolescent Major Depressive Disorder.Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder.Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder.A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Vilazodone in Adolescents with Major Depressive Disorder.
P2860
Q33896686-32EB305E-4F06-4167-8091-03CE54CE9C38Q36981110-7F29ED1E-D1EB-486E-8D5A-D558617C58C2Q38602146-FE8CDF6F-454C-4E8B-8DB3-AFBBBAA6B642Q38850169-752427F9-3D40-4817-BE5C-3A78628E3E12Q38969019-921D63C2-5398-487B-9657-7338F2137070Q38989665-574C93A1-D631-4D33-8033-3A55E661438CQ39043925-D75BA243-9253-486A-A4E4-F3EA01661C8DQ39878590-8060AFB6-8042-47FC-B9BC-352F155518E1Q42669945-BC8F1AC4-598C-4563-810C-D5407A933D5EQ47165527-95B834B3-0407-4EF8-BEDE-C9C30EB23F15Q47582630-7245A422-588A-41D8-80C7-9D6BA74DF4C2Q47692217-442025E2-5E81-4E7C-ACEC-642A1338A2DEQ47693093-4E4DC063-A26D-41B1-ADB7-BD0D0F09049FQ53414630-BDA48616-9D54-4911-B6A9-6D3A48B682EA
P2860
A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
A double-blind efficacy and sa ...... with major depressive disorder
@ast
A double-blind efficacy and sa ...... with major depressive disorder
@en
type
label
A double-blind efficacy and sa ...... with major depressive disorder
@ast
A double-blind efficacy and sa ...... with major depressive disorder
@en
prefLabel
A double-blind efficacy and sa ...... with major depressive disorder
@ast
A double-blind efficacy and sa ...... with major depressive disorder
@en
P2093
P2860
P356
P1476
A double-blind efficacy and sa ...... with major depressive disorder
@en
P2093
Apurva Prakash
Beth A Pangallo
Graham J Emslie
John S March
Mark E Bangs
P2860
P304
P356
10.1089/CAP.2013.0096
P577
2014-05-09T00:00:00Z